士泽生物医药（苏州）有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
XellSmart Completed World's First Patient Dosing in its Registrational Clinical trial for iPSC-derived Subtype-specific Neural Cell Therapy for Spinal Cord Injury 2025-07-28 21:10
XellSmart Secures FDA Clearance for Three Phase I INDs of Allogeneic iPSC-Derived Cell Therapies Targeting Major CNS Diseases: Parkinson's Diseases, Spinal Cord Injury and ALS 2025-06-03 09:00
World's First -- XellSmart's Allogeneic iPSC-derived Regenerative Cell Therapy for Spinal Cord Injury Officially Approved by the U.S. FDA for a Registrational Phase I Clinical Trial 2025-05-26 09:00
XellSmart's Allogeneic iPSC-derived Cell Therapies for Parkinson's Disease and ALS Officially Approved by the U.S. FDA for Phase I Clinical Trials 2025-04-15 21:10
1